News Formal

23andMe Is Sinking Fast. Can the Company Survive?

  • 📰 WIREDScience
  • ⏱ Reading Time:
  • 25 sec. here
  • 6 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 55%

Science Notícia

Business,Genetics,Whole-Genome Sequencing

The home DNA testing boom is over, and 23andMe is running out of options.

In August, the company shuttered its in-house drug discovery unit. And last month, all of the company’s board of directors resigned en masse over cofounder and CEO Anne Wojcicki’s “strategic direction,” which included a proposal to take the company private at 40 cents per share. Wojcicki had said she would consider third-party takeover offers but reversed course in a regulatory filing this week.

It partnered with Genentech back in 2015, and when that ended, it struck an exclusive deal with GlaxoSmithKline in 2018. The pharma company invested $300 million in 23andMe, but that agreement expired in 2023, with no big partners stepping in to fill Glaxo’s shoes. And while 23andMe recently shut down its drug discovery unit, it is continuing to advance the drug candidates it already has in clinical trials. Now, the company has turned to growing its telehealth business.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 385. in BR
 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

23andMe directors resign as the CEO of the genetic-testing company seeks to take it privateAll of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the genetic-testing company.
Fonte: ksatnews - 🏆 442. / 53 Consulte Mais informação »

23andMe directors resign as the CEO of the genetic-testing company seeks to take it privateAll of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the genetic-testing company. The resignations follow drawn-out negotiations with 23andMe CEO and co-founder Anne Wojcicki who wants to take the company private.
Fonte: AP - 🏆 728. / 51 Consulte Mais informação »

23andMe directors resign as the CEO of the genetic-testing company seeks to take it privateAll of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the genetic-testing company.
Fonte: wjxt4 - 🏆 246. / 63 Consulte Mais informação »